B. Metzler Seel. Sohn & Co. Ag Nurix Therapeutics, Inc. Transaction History

B. Metzler Seel. Sohn & Co. Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$4.25 - $10.71 $38,815 - $97,814	9,133 Added 33.78%	36,171 $373,000
Q3 2023 Nov 13, 2023	SELL	$7.86 - $10.08 $212,518 - $272,543	-27,038 Reduced 50.0%	27,038 $212,000
Q2 2023 Aug 11, 2023	BUY	$8.7 - $13.28 $319,629 - $487,893	36,739 Added 211.91%	54,076 $540,000
Q1 2023 May 10, 2023	BUY	$8.56 - $13.26 $38,742 - $60,014	4,526 Added 35.33%	17,337 $153,000
Q4 2022 Feb 13, 2023	BUY	$9.86 - $14.59 $23,841 - $35,278	2,418 Added 23.27%	12,811 $140,000
Q3 2022 Nov 14, 2022	BUY	$12.33 - $19.81 $128,145 - $205,885	10,393 New	10,393 $135,000

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $923M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of B. Metzler Seel. Sohn & Co. Ag, based on Form 13F filings with the SEC.

Stay updated on B. Metzler Seel. Sohn & Co. Ag with notifications on news.